statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Excess Deaths In Japan Hit 115,000 Following 3rd COVID Shot; New Study Explains Why

 Authored by Joe Wang via The Epoch Times (emphasis ours),

A new study on harms resulting from the...

Excess Deaths In Japan Hit 115,000 Following 3rd COVID Shot; New Study Explains Why

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
read more...

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday

Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent...

Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings

Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year...

Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year

US Futures Tumble After Facebook Implodes; GDP Data On Deck

 The three-day rebound from last week's rout ended with a thud after the close yesterday when Meta imploded, plunging as much...

US Futures Tumble After Facebook Implodes; GDP Data On Deck

Sanofi Sales, Profit Beat Expectations...

Sanofi Sales, Profit Beat Expectations

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts 150 cells/ L and 300...

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.
read more...

Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Volume	280.00
52-Wk High	$55.93
52-Wk Low	$42.63

SNY Sanofi-Aventis

About

Feed

News

Sentiment

Fundamentals